Learn how to contact trace COVID-19 with UH's new, online course. Photo by Getty Images

As the nationwide battle against COVID-19 surges on, the University of Houston is launching a free new program to train locals how to identify and warn potentially exposed individuals throughout the region.

The new contact tracing and case identification certificate program — dubbed Epi Corps for Epidemiology Corps — is meant to train up a new type of so-called "disease detective" to combat coronavirus. The 12-hour, online course is currently open to UH students, faculty, and staff — and will soon be made available to the general public, according to the university.

This comes as the Houston Health Department last week announced plans to add 300 new contact tracers in addition to the 300 disease detectives Harris County Public Health plans to recruit. More than 100,000 trained contact tracers will be needed across the country to address COVID-19, according to a report by Johns Hopkins University. Texas Gov. Greg Abbott's plan to reopen the state calls for some 4,000 contact tracers to be hired statewide by mid-May.

The goal for the Epi Corps training program is to be scaled statewide, as Texas lags in per-capita testing for coronavirus, ranking 47th out of 50 states. "We really do not have a good handle on how many people have been exposed or how many people are asymptomatic carriers, making contact tracing critically important," said program organizer, Bettina Beech, in a statement.

Contact tracing is considered crucial in the fight against COVID-19, teamed with social distancing, stay-at-home mandates, and good hygiene practices. The Center for Disease Control warns if communities are unable to effectively isolate patients and ensure contacts can separate themselves from others, rapid community spread of COVID-19 is likely to increase to the point that strict mitigation strategies will again be needed to contain the virus.

Through this new program, the corps staffers could be deployed to work on-site at the city and county health departments to assist COVID-19 patients recall everyone they've had close contact with leading up to their infection. The contact tracers would then notify those contacts of their potential exposure and provide education, support, and information to understand their risk.

The contact tracers-in-training will be trained on COVID-19 signs and symptoms, epidemiology, medical terminology, cultural competency, interpersonal communication and interviewing skills, patient confidentiality, and more, according to the school. Those who successfully complete the course will receive a digital certificate, and some students will be eligible to earn credit hours.

The Epi Corps curriculum will be administered via the Blackboard digital learning platform. Plans are moving forward to make a shorter program available to the community at large, including small businesses, in the coming weeks.

The training follows a format similar to the Centers for Disease Control and Prevention contact tracing training program for tuberculosis and is based on the Association of State and Territorial Health Officials contact tracing training modules, according to UH.

"Contact tracing, along with large-scale testing, is a critical component to reopening our state and to stimulate the economy, but the national and local public health infrastructure does not have the capacity to handle this task alone," said Dr. Stephen Spann, founding dean of the UH College of Medicine, in a statement. "As a public university dedicated to serving the community, it's incumbent upon us to step up and provide the necessary training so we can get through this crisis together."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

27 Houston companies make Fortune 500 for 2026, led by energy giants

Houston HQs

Editor's note: This article has been updated to correct the number of companies based in the Dallas-Fort Worth area.

Houston is a giant among U.S. hubs for corporate headquarters.

The 2026 Fortune 500 lists 27 companies based in the Houston area, with many energy companies claiming top spots. Houston ties with Chicago for the second-most Fortune 500 headquarters, preceded only by New York City (53). Dallas-Fort Worth is home to 24 Fortune 500 headquarters.

Texas leads the nation for Fortune 500 headquarters (57), with California in the No. 2 spot and New York at No. 3.

“Texas is the undisputed headquarters of headquarters,” Gov. Greg Abbott said in a news release. “The world’s leading businesses invest with confidence in Texas because of our welcoming business climate, predictable regulatory environment, and skilled and growing workforce. People and businesses are choosing Texas because Texas works.”

The 2026 Fortune 500 ranks the largest U.S. corporations based on revenue in fiscal year 2025.

Here’s a rundown of the 27 Fortune 500 companies based in the Houston area.

  • No. 9 ExxonMobil
  • No. 21 Chevron
  • No. 29 Phillips 66
  • No.55 Sysco
  • No. 75 ConocoPhillips
  • No. 89 Enterprise Products Partners
  • No. 103 Plains GP Holdings
  • No. 133 Hewlett Packard Enterprise
  • No. 149 NRG Energy
  • No. 157 Quanta Services
  • No. 164 Baker Hughes
  • No. 173 Occidental Petroleum
  • No. 179 Waste Management
  • No. 201 EOG Resources
  • No. 204 Group 1 Automotive
  • No. 207 Halliburton
  • No. 223 Cheniere Energy
  • No. 236 Corebridge Financial
  • No. 262 Targa Resources
  • No. 266 Kinder Morgan
  • No. 388 Westlake
  • No. 435 CenterPoint Energy
  • No. 438 APA
  • No. 440 Comfort Systems USA
  • No. 455 NOV
  • No. 488 KBR
  • No. 496 Coterra Energy. Oklahoma City, Oklahoma-based Devon Energy and Houston-based Coterra Energy merged in early May, with the combined company retaining the Devon Energy name and the Houston headquarters.

The Greater Houston Partnership notes the Houston area soon will welcome its 28th Fortune 500 company. Expand Energy (formerly Chesapeake Energy), appearing at No. 362 on the 2026 list, says it’s moving its headquarters from Oklahoma City to Spring this year.

As the natural gas producer prepares to relocate to Texas, it’s hunting for a new leader. Nick Dell’Osso stepped down as president and CEO earlier this year. Board Chairman Michael Wichterich is interim president and CEO.

Dell’Osso became president and CEO of Oklahoma City-based Gulfport Energy effective May 28.

---

This article first appeared on EnergyCapitalHTX.com.